Deep-learning of digital histopathology, radiomics and clinical factors to develop precision medicine with first-line gemcitabine-cisplatin-nivolumab for metastatic urothelial carcinoma: analysis of the CHECKMATE901 Phase III trial
-
Enrollment
This study is not currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Sponsor
AdventHealth CFD